초록 ▼

A novel strain of Lactobacillus plantarum , referred to as LB931, has now been isolated. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 can be used for treating and/or preventing urogenital

A novel strain of Lactobacillus plantarum , referred to as LB931, has now been isolated. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 can be used for treating and/or preventing urogenital infections. LB931 can advantageously be included in pharmaceutical compositions and in products for personal care, such as feminine hygiene products, diapers and sanitary napkins.

대표청구항 ▼

1. A biologically pure strain of Lactobacillus plantarum strain LB931, said strain has been assigned accession number DSM11918. 2. A pharmaceutical composition comprising Lactobacillus plantarum , strain LB931, which has been deposited at Deutsche Sammlung von Mirkoorganismen, and been assigned ac

1. A biologically pure strain of Lactobacillus plantarum strain LB931, said strain has been assigned accession number DSM11918. 2. A pharmaceutical composition comprising Lactobacillus plantarum , strain LB931, which has been deposited at Deutsche Sammlung von Mirkoorganismen, and been assigned accession number DSM11918, together with a pharmaceutically acceptable carrier and/or diluent. 3. A pharmaceutical composition according to claim 2, further comprising other lactic acid bacteria. 4. A pharmaceutical composition according to claim 2 comprising 10 4 to 10 11 colony forming units, Lactobacillus plantarum LB931. 5. A pharmaceutical composition according to claim 4, wherein said pharmaceutically acceptable carrier is skimmed milk, or a lactobacillus growth medium in powder form. 6. A pharmaceutical composition according to claim 2 which is a suspension, spray, gel, cream, powder, capsule or a vaginal insert. 7. The pharmaceutical composition according to claim 2, wherein said Lactobacillus plantarum LB931 is in an amount of 10 5 to 10 9 cfu. 8. An absorbent product comprising Lactobacillus plantarum strain LB931, said strain has been assigned accession number DSM11918. 9. An absorbent product according to claim 8, comprising 10 4 to 10 11 cfu, Lactobacillus plantarum LB931. 10. The absorbent product according to claim 9, wherein LB931 is an amount of 10 5 to 10 9 cfu. 11. The absorbent product according to claim 8, wherein said absorbent product is selected from the group consisting of a feminine hygiene product, diaper, sanitary napkin, panty guard and incontinence guard. 12. A method of preparing a pharmaceutical composition for preventing and/or treating urogenital infections, comprising:adding Lactobacillus plantarum , strain LB931, said strain has been assigned accession number DSM11918 to said pharmaceutical composition. 13. The method according to claim 12, wherein said pharmaceutical composition prevents or inhibits the growth of enterobacteria. 14. The method according to claim 12, wherein said absorbent product prevents or treats the growth of enterobacteria. 15. The method according to claim 14, wherein said absorbent product is selected from the group consisting of a diaper, sanitary napkin, panty guard, incontinence guard and feminine hygiene product. 16. A method of preparing an absorbent product suitable for preventing and/or treating urogenital infections, comprising:adding Lactobacillus plantarum , strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and has been assigned accession number DSM11918 to said absorbent product. 17. A method for preventing and/or treating urogenital infections in a patient, comprising:administering Lactobacillus plantarum , strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and has been assigned accession number DSM11918 in an effective amount to said patient. 18. The method according to claim 17, wherein said Lactobacillus plantarum is administered to said patient via a pharmaceutical composition selected from the group consisting of ointments, creams, liquid solutions, suppositories, and capsules. 19. The method according to claim 17, wherein said Lactobacillus plantarum is administered to said patient by placing an absorbent product containing Lactobacillus plantarum in close contact with the skin of said patient, said absorbent product selected from the group consisting of a diaper, sanitary napkin, panty guard, incontinence guard and feminine hygiene product. 20. The method according to claim 19, wherein said absorbent product prevents or treats the growth of enterobacteria.